Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital |
Park, Mi Seon
(Department of Pharmacy, College of Pharmacy, Chosun University)
Yang, Young-Mo (Department of Pharmacy, College of Pharmacy, Chosun University) Park, Ki Hyun (Department of Pharmacy, College of Pharmacy, Chosun University) Yoon, Hyonok (Department of Pharmacy, Research Institute of Pharmaceutical Sciences, Gyeongsang National University) Kim, Ju Sin (Department of Pharmacy, Jeonbuk National University Hospital) Choi, Eun Joo (Department of Pharmacy, College of Pharmacy, Chosun University) |
1 | Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65(4):727-33. DOI |
2 | Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65(4):719-26. DOI |
3 | Su F, Ioannou GN. Hepatocellular carcinoma risk after direct-acting antiviral therapy. Clin Liver Dis (Hoboken) 2019;13(1):6-12. DOI |
4 | Ravi S, Axley P, Jones D, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152(4):911-2. DOI |
5 | Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378(4):354-69. DOI |
6 | World Health Organization. Hepatitis C (Newsroom/fact sheets). Available from http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed February 27, 2020. |
7 | World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection - July 2018. Available from https://www.who.int/publications/i/item/9789241550345. Accessed March 19, 2022. |
8 | World Health Organization. Global hepatitis report, 2017. Available from http://www.who.int/hepatitis/publications/global-hepatitisreport2017/en/. Accessed February 27, 2020. |
9 | Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62(2):409-16. DOI |
10 | Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvirbased treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag 2017;13:477-97. DOI |
11 | Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV Infection. N Engl J Med 2017;376(22):2134-46. DOI |
12 | Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66(2):389-97. DOI |
13 | Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2016;22(1):76-139. DOI |
14 | Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-70. DOI |
15 | Gayam V, Hossain MR, Khalid M, et al. Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C/human immunodeficiency virus coinfection in a community care setting. Gut Liver 2018;12(6):694-703. DOI |
16 | Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. DOI |
17 | Miotto N, Mendes LC, Zanaga LP, et al. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13(7):e0199941. DOI |
18 | Chen P, Ma A, Liu Q. Cost-effectiveness of elbasvir/grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1b infection in China. Clin Drug Investig 2018;38(11):1031-9. DOI |
19 | Darvishian M, Wong S, Binka M, et al. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat 2020;27(3):243-60. DOI |
20 | Levin JM, Dabirshahsahebi S, Bauer M, Huckins E. Retrospective analysis of hepatitis C infected patients treated through an integrated care model. World J Gastroenterol 2016;22(38):8558-67. DOI |
21 | Costa VD, Pellegrini P, Rotman V, et al. Resistance mutations A30K and Y93N associated with treatment failure with sofosbuvir and daclatasvir for hepatitis C virus infection non-responder patients: case reports. Viruses 2019;11(11):1004. DOI |
22 | Olea Jr. A, Grochowski J, Luetkemeyer AF, Robb V, Saberi P. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. Integr Pharm Res Pract 2018;7:105-11. DOI |
23 | Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. DOI |
24 | Jeong SH, Jang ES, Choi HY, Kim KA, Chung WK, Ki M. Current status of hepatitis C virus infection and countermeasures in South Korea. Epidemiol Health 2017;39:e2017017. DOI |
25 | Ahmed AM, Doheim MF, Mattar OM, et al. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol 2018;90(5):907-18. DOI |
26 | Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV Infection: 2 phase 3 randomized trials. Gastroenterology 2017;153(1):113-22. DOI |
27 | Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24(3):169-229. DOI |
28 | Yang Y, Wu FP, Wang WJ, et al. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019;25(44):6551-60. DOI |
29 | Yamamoto H, Ikesue H, Ikemura M, et al. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci 2018;4(1):1-8. DOI |
30 | Yu ML, Hung CH, Huang YH, et al. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118(2):556-64. DOI |